NeuroPace Inc (NPCE) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, NeuroPace Inc's filing signal turned positive.

NeuroPace, Inc. is a medical device company focused on treating drug-resistant focal epilepsy with its RNS System, a brain-responsive neuromodulation device that continuously monitors brain activity and delivers personalized electrical pulses to prevent seizures. The RNS System is the only device that records continuous brain activity data, allowing for remote patient monitoring and data-driven treatment optimization. Currently indicated for adults with drug-resistant focal epilepsy in the U.S., NeuroPace is pursuing expanded FDA labeling for generalized epilepsy and pediatric patients. The company markets its system through a direct sales force primarily to epilepsy centers and aims to broaden its reach into the community setting. With over 8,000 patients treated as of December 31, 2025, NeuroPace leverages its extensive brain data set to improve therapy effectiveness and explore applications in other neurological disorders.

Revenue is primarily driven by sales of the RNS System to hospital facilities for initial implant procedures and replacement implants. The company also generated revenue from a distribution agreement for DIXI Medical products, which concluded at the end of 2025, and from services provided under a collaboration agreement.